QOP
VKTX icon

Quinn Opportunity Partners’s Viking Therapeutics VKTX Stock Holding History

Quinn Opportunity Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-403,445
Closed -$10.6M – 414
2025
Q3 		$10.6M Buy
403,445
+135,673
+51% +$4.05M 0.75% 31
2025
Q2 		$7.1M Buy
267,772
+24,000
+10% +$632K 0.59% 49
2025
Q1 		$5.89M Buy
243,772
+159,883
+191% +$5.05M 0.4% 70
2024
Q4 		$3.38M Buy
+83,889
New +$4.78M 0.23% 109
2024
Q3 		– Sell
-49,000
Closed -$2.6M – 320
2024
Q2 		$2.6M Buy
49,000
+28,000
+133% +$1.84M 0.3% 76
2024
Q1 		$1.72M Buy
+21,000
New +$934K 0.19% 102

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quinn Opportunity Partners's VKTX Position: Q4 2025 in Review

Quinn Opportunity Partners sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 403,445 shares — an estimated $10.6M sold.

Quinn Opportunity Partners first reported a position in VKTX in Q1 2024 and held it in 6 quarters. The position peaked at $10.6M in Q3 2025. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • Quinn Opportunity Partners reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quinn Opportunity Partners sold 403,445 Viking Therapeutics shares in Q4 2025, an estimated $10.6M.
  • Quinn Opportunity Partners first reported a position in Viking Therapeutics in Q1 2024 and held it in 6 quarters.
  • Quinn Opportunity Partners's Viking Therapeutics position peaked at $10.6M in Q3 2025.
  • 426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Quinn Opportunity Partners's 13F filing for Q4 2025, filed 13 Feb 2026.